The Latest: 澳洲幸运排列五开奖结果_澳洲体彩排列五开奖公告_幸运澳洲排列五开奖结果查询

• 

  FDA’s platform designation aims to ease R&D pain points

  A new program creates approval pathways for multiple drugs developed on the same platform. 

  Biotech

• 

  Behind Big Pharma’s layoffs — is there an end in sight?

  A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

  Biotech

• 

  Pharma’s R&D gamble: picking pipeline winners in a risky field

  How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

  Biotech

• 

  A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

  Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

  Biotech

• 

  Biotech Spotlight

  Regenerative cell therapy biotech uses IPO to blast into human trials

  Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

  Biotech

• 

  Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

  Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

  Biotech

• 

  What’s in a drug name? More than you might think.

  From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.

  Commercialization

• 

  Q&A

  In an era of big patent losses, drug launches need years of runway

  Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

  Biotech

• 

  After two Big Pharma deals, Nimbus looks to keep the hits coming

  With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.

  Biotech

• 

  Deadline looms for Chinese biotech contracts

  The latest version of The Biosecure Act working its way through Congress could make waves in the U.S. biotech industry.

  Biotech

• 

  As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’

  To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.

  Leadership

• 

  Biotech Spotlight

  Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges

  By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.

  Biotech

• 

  FTC request may signal trouble for Novo/Catalent deal

  As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.

  Manufacturing

• 

  Can robots break the cell therapy bottleneck?

  澳洲幸运彩官网开奖结果查询亮点, 历史数据开奖号码查询直播, 彩票开奖查询开奖结果查询 A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

  Biotech

• 

  As weight loss booms, drugmakers look for an edge with oral options

  Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.  

  Pharma

• 

  Where competition is heating up in pharma

  The stage is set for potential blockbuster-level showdowns targeting these three indications.

  Biotech

• 

  Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

  Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.  

  Commercialization

• 

  AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets

  Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

  Biotech

• 

  Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field

  Companies like UpScriptHealth led the charge with online prescriptions decades ago, and now the industry is catching on to solve some of healthcare’s most pressing issues.

  Patient

• 

  3 up-and-coming US biotech hotspots

  These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.

  Biotech

• 

  After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era

  Heather Dean discusses the company’s neuroscience pipeline in epilepsy and narcolepsy and moving from a mass market to a rare disease mentality.

  Commercialization

• 

  Why AlphaFold 3 is stirring up so much buzz in pharma

  The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.

  Biotech

• 

  Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies

  Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said. 

  Biotech

• 

  Investors put $400M into biotech licensing obesity drugs from China

  The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

  Biotech

• 

  Why H5N1 has scientists and regulators on edge

  While the H5N1 threat to humans is still low, the recent influenza outbreak in cattle is presenting strange and challenging hurdles for containment.

  Pharma